Current position

J.P. Morgan Asset Management’s Biontech Se (BNTX) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

JPMorgan Chase & Co. (consolidated SEC filer)Verified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2021Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares126.98KHighest verified quarter-end share count
Quarters reported17Verified quarters with shares above zero
What happened?

JPMorgan Chase & Co. (consolidated SEC filer) first reported Biontech Se in Q3 2021. The reported position was increased and reduced across later filings. JPMorgan Chase & Co. (consolidated SEC filer) currently reports 126.98K shares. The latest verified filing showed: Bought 8.3% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 8.3% more+9.71K shares · 126.98K shares reported after the change
Filing context

Quarter-end price $94.26

Q1 2026
Bought 4.1% more+4.57K shares · 117.27K shares reported after the change
Filing context

Quarter-end price $85.25

Q4 2025
Bought 87.3% more+52.54K shares · 112.70K shares reported after the change
Filing context

Quarter-end price $95.20

Q3 2025
Sold 7.1% of the position−4.62K shares · 60.16K shares remained
Filing context

Quarter-end price $98.62

Q2 2025
Bought 3,555.4% more+63.00K shares · 64.77K shares reported after the change
Filing context

Quarter-end price $106.47

Q1 2025
Sold 82.4% of the position−8.32K shares · 1.77K shares remained
Filing context

Quarter-end price $91.06

Portfolio importance

How important is Biontech Se in JPMorgan Chase & Co. (consolidated SEC filer)’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#2660of 7720 reported positions
Peak portfolio weight0.0%Q3 2021
Best historical rank#2407Q3 2021
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$99.262026-09-24

Market context only; not an investor transaction price.

Latest filing quarter-end price$94.26Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-12
Open SEC filing ↗

The reported holdings and portfolio value cover JPMorgan Chase & Co.'s consolidated 13F filing, not J.P. Morgan Asset Management alone, a single fund, or the firm's total assets under management. The displayed holdings and history are bounded selections; weights use the full reported 13F value. Portfolio performance is not published, and position-level estimates remain withheld unless their evidence gates pass.